Lilly to present new rheumatoid arthritis findings at ACR/ARHP 2017

Lilly and Incyte are presenting new clinical data on their latest rheumatoid arthritis research at this week's American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting.

The companies are attending the conference in San Diego and sharing research data showing how patients with moderate-to-severe rheumatoid arthritis treated with the new drug baricitinib reported greater improvements in pain control than an established alternative.

A new post-hoc analysis of the phase III RA-BEAM study disclosing outcomes of patient-reported levels of pain control will be presented during the conference, showing how treatment with baricitinib can deliver faster pain improvement than current therapies.

Dr James McGill, distinguished medical fellow and global brand development leader at Lilly Bio-Medicines, said: "We are pleased to share these data suggesting that baricitinib could provide a potential new option for people living with rheumatoid arthritis. We remain committed to making life better for people with rheumatoid arthritis and improving patient care."

Baricitinib has already been approved for the treatment of adult patients with rheumatoid arthritis in the EU and Japan, but Lilly is still seeking approval of the drug in the US.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.